PerkinElmer to buy SIRION Biotech

PerkinElmer Inc. (PKI) agreed to buy SIRION Biotech GmbH, a provider of viral vector-based technologies that drive improved delivery performance for cell and gene therapies. The acquisition is expected to close during the third quarter of 2021.

Headquartered in Munich, Germany, privately held SIRION has about 50 employees based in Germany, the U.S. and France.

The deal will complement PerkinElmer's Horizon Discovery portfolio which includes gene editing and modulation tools for CRISPR, CRISPRi and RNAi, custom cell lines for bio production and base editing technologies, PerkinElmer said in a statement.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Revvity. (2023, August 23). PerkinElmer to buy SIRION Biotech. News-Medical. Retrieved on June 23, 2024 from https://www.news-medical.net/news/20210624/PerkinElmer-to-buy-SIRION-Biotech.aspx.

  • MLA

    Revvity. "PerkinElmer to buy SIRION Biotech". News-Medical. 23 June 2024. <https://www.news-medical.net/news/20210624/PerkinElmer-to-buy-SIRION-Biotech.aspx>.

  • Chicago

    Revvity. "PerkinElmer to buy SIRION Biotech". News-Medical. https://www.news-medical.net/news/20210624/PerkinElmer-to-buy-SIRION-Biotech.aspx. (accessed June 23, 2024).

  • Harvard

    Revvity. 2023. PerkinElmer to buy SIRION Biotech. News-Medical, viewed 23 June 2024, https://www.news-medical.net/news/20210624/PerkinElmer-to-buy-SIRION-Biotech.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Changing the landscape of R&D to build clinical success from the ground up